| Year |
Citation |
Score |
| 2020 |
Zádori D, Szalárdy L, Reisz Z, Kovacs GG, Maszlag-Török R, Ajeawung NF, Vécsei L, Campeau PM, Klivényi P. Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the Gene. Frontiers in Neurology. 11: 767. PMID 32849222 DOI: 10.3389/Fneur.2020.00767 |
0.305 |
|
| 2020 |
Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert Opinion On Pharmacotherapy. 1-14. PMID 32808807 DOI: 10.1080/14656566.2020.1806237 |
0.422 |
|
| 2020 |
Takáts A, Aschermann Z, Vécsei L, Klivényi P, Dézsi L, Zádori D, Valikovics A, Varannai L, Onuk K, Kinczel B, Kovács N. [Advanced Parkinson's disease characteristics in clinical practice: Results from the OBSERVE-PD study and sub-analysis of the Hungarian data]. Ideggyogyaszati Szemle. 73: 261-268. PMID 32750243 DOI: 10.18071/Isz.73.0261 |
0.374 |
|
| 2020 |
Nánási N, Veres G, Cseh EK, Martos D, Hadady L, Klivényi P, Vécsei L, Zádori D. The assessment of possible gender-related effect of endogenous striatal alpha-tocopherol level on MPTP neurotoxicity in mice. Heliyon. 6: e04425. PMID 32685739 DOI: 10.1016/J.Heliyon.2020.E04425 |
0.412 |
|
| 2020 |
Salamon A, Maszlag-Török R, Veres G, Boros FA, Vágvölgyi-Sümegi E, Somogyi A, Vécsei L, Klivényi P, Zádori D. Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntington's Disease. Neurochemical Research. PMID 32524313 DOI: 10.1007/S11064-020-03069-0 |
0.387 |
|
| 2020 |
Boros FA, Maszlag-Török R, Vécsei L, Klivényi P. Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson's disease. Brain Research. 1730: 146672. PMID 31953211 DOI: 10.1016/J.Brainres.2020.146672 |
0.346 |
|
| 2019 |
Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Neuroprotection in Parkinson's disease: facts and hopes. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 31828513 DOI: 10.1007/S00702-019-02115-8 |
0.393 |
|
| 2019 |
Illés A, Csabán D, Grosz Z, Balicza P, Gézsi A, Molnár V, Bencsik R, Gál A, Klivényi P, Molnar MJ. The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials. Frontiers in Genetics. 10: 1061. PMID 31737044 DOI: 10.3389/Fgene.2019.01061 |
0.32 |
|
| 2019 |
Salamon A, Zádori D, Szpisjak L, Klivényi P, Vécsei L. Opicapone for the treatment of Parkinson's disease: an update. Expert Opinion On Pharmacotherapy. 1-7. PMID 31670988 DOI: 10.1080/14656566.2019.1681971 |
0.338 |
|
| 2019 |
Boros FA, Török R, Vágvölgyi-Sümegi E, Pesei ZG, Klivényi P, Vécsei L. Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients. Neuroscience Letters. 706: 140-145. PMID 31085292 DOI: 10.1016/J.Neulet.2019.05.014 |
0.367 |
|
| 2019 |
Szpisjak L, Zadori D, Klivenyi P, Vecsei L. Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias. Cns & Neurological Disorders Drug Targets. PMID 30864514 DOI: 10.2174/1871527318666190311155846 |
0.313 |
|
| 2019 |
Salamon A, Torok R, Sumegi E, Boros F, Pesei ZG, Fort Molnar M, Veres G, Zadori D, Vecsei L, Klivenyi P. The effect of physical stimuli on the expression level of key elements in mitochondrial biogenesis. Neuroscience Letters. 698: 13-18. PMID 30611892 DOI: 10.1016/J.Neulet.2019.01.003 |
0.316 |
|
| 2018 |
Klivényi P, Vécsei L. [The treatment of advanced Parkinson's disease]. Ideggyogyaszati Szemle. 71: 377-383. PMID 30604936 DOI: 10.18071/Isz.71.0377 |
0.323 |
|
| 2018 |
Boros FA, Klivényi P, Toldi J, Vécsei L. Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington's disease. Expert Opinion On Therapeutic Targets. 1-13. PMID 30449219 DOI: 10.1080/14728222.2019.1549231 |
0.351 |
|
| 2018 |
Szalardy L, Molnar MF, Zadori D, Cseh EK, Veres G, Kovacs GG, Vecsei L, Klivenyi P. Non-motor Behavioral Alterations of PGC-1α-Deficient Mice - A Peculiar Phenotype With Slight Male Preponderance and No Apparent Progression. Frontiers in Behavioral Neuroscience. 12: 180. PMID 30210314 DOI: 10.3389/Fnbeh.2018.00180 |
0.315 |
|
| 2018 |
Zádori D, Veres G, Szalárdy L, Klivényi P, Vécsei L. Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. Journal of Alzheimer's Disease : Jad. 62: 523-547. PMID 29480191 DOI: 10.3233/Jad-170929 |
0.344 |
|
| 2017 |
Tripolszki K, Török D, Goudenège D, Farkas K, Sulák A, Török N, Engelhardt JI, Klivényi P, Procaccio V, Nagy N, Széll M. High-throughput sequencing revealed a novel SETX mutation in a Hungarian patient with amyotrophic lateral sclerosis. Brain and Behavior. 7: e00669. PMID 28413711 DOI: 10.1002/Brb3.669 |
0.312 |
|
| 2017 |
Juhász A, Aschermann Z, Ács P, Janszky J, Kovács M, Makkos A, Harmat M, Tényi D, Karádi K, Komoly S, Takáts A, Tóth A, Nagy H, Klivényi P, Dibó G, et al. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study. Parkinsonism & Related Disorders. PMID 28185758 DOI: 10.1016/J.Parkreldis.2017.02.001 |
0.353 |
|
| 2017 |
Torok R, Salamon A, Sumegi E, Zadori D, Veres G, Molnar MF, Vecsei L, Klivenyi P. Effect of MPTP on mRNA expression of PGC-1α in mouse brain. Brain Research. PMID 28161458 DOI: 10.1016/J.Brainres.2017.01.032 |
0.305 |
|
| 2016 |
Aschermann Z, Dibó G, Klivényi P, Kovács N, Kovács T, Takáts A, Tamás G, Varannai L. [Recommendation for treatment options in advanced Parkinson's disease]. Ideggyogyaszati Szemle. 69: 367-372. PMID 29733553 DOI: 10.18071/Isz.69.0367 |
0.337 |
|
| 2016 |
Molnár MF, Török R, Szalárdy L, Sümegi E, Vécsei L, Klivényi P. High-dose 1,25-dihydroxyvitamin D supplementation elongates the lifespan of Huntington's disease transgenic mice. Acta Neurobiologiae Experimentalis. 76: 176-81. PMID 27685770 DOI: 10.21307/Ane-2017-017 |
0.371 |
|
| 2016 |
Tamás G, Kelemen A, Radics P, Valálik I, Heldman D, Klivényi P, Vécsei L, Hidasi E, Halász L, Kis D, Barsi P, Golopencza P, Erőss L. Effect of subthalamic stimulation on distal and proximal upper limb movements in Parkinson's disease. Brain Research. PMID 27543337 DOI: 10.1016/J.Brainres.2016.08.019 |
0.311 |
|
| 2016 |
Ács P, Molnár MJ, Klivényi P, Kálmán B. [GENETICALLY DETERMINED DISEASES ASSOCIATED WITH PATHOLOGICAL BRAIN IRON ACCUMULATION AND NEURODEGENERATION]. IdeggyóGyáSzati Szemle. 69: 157-66. PMID 27468605 DOI: 10.18071/Isz.69.0157 |
0.306 |
|
| 2016 |
Szalardy L, Molnar M, Torok R, Zadori D, Kovacs GG, Vecsei L, Klivenyi P. Lack of age-related clinical progression in PGC-1α-deficient mice - implications for mitochondrial encephalopathies. Behavioural Brain Research. PMID 27424777 DOI: 10.1016/J.Bbr.2016.07.021 |
0.401 |
|
| 2016 |
Szalardy L, Molnar M, Torok R, Zadori D, Vecsei L, Klivenyi P, Liberski P, Kovacs GG. Histopathological comparison of Kearns-Sayre syndrome and PGC-1α-deficient mice suggests a novel concept for vacuole formation in mitochondrial encephalopathy. Folia Neuropathologica / Association of Polish Neuropathologists and Medical Research Centre, Polish Academy of Sciences. 54: 9-22. PMID 27179217 DOI: 10.5114/Fn.2016.58911 |
0.354 |
|
| 2016 |
Zádori D, Veres G, Szalárdy L, Klivényi P, Fülöp F, Toldi J, Vécsei L. Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015). Expert Opinion On Therapeutic Patents. PMID 27172114 DOI: 10.1080/13543776.2016.1189531 |
0.305 |
|
| 2015 |
Török R, Zádori D, Török N, Csility É, Vécsei L, Klivényi P. An assessment of the frequency of mutations in the GBA and VPS35 genes in Hungarian patients with sporadic Parkinson's disease. Neuroscience Letters. PMID 26547032 DOI: 10.1016/J.Neulet.2015.11.001 |
0.305 |
|
| 2015 |
Szalárdy L, Zádori D, Klivényi P, Toldi J, Vécsei L. Electron Transport Disturbances and Neurodegeneration: From Albert Szent-Györgyi's Concept (Szeged) till Novel Approaches to Boost Mitochondrial Bioenergetics. Oxidative Medicine and Cellular Longevity. 2015: 498401. PMID 26301042 DOI: 10.1155/2015/498401 |
0.395 |
|
| 2015 |
Török N, Török R, Szolnoki Z, Somogyvári F, Klivényi P, Vécsei L. The Genetic Link between Parkinson's Disease and the Kynurenine Pathway Is Still Missing. Parkinson's Disease. 2015: 474135. PMID 25785227 DOI: 10.1155/2015/474135 |
0.34 |
|
| 2015 |
Veres G, Molnár M, Zádori D, Szentirmai M, Szalárdy L, Török R, Fazekas E, Ilisz I, Vécsei L, Klivényi P. Central nervous system-specific alterations in the tryptophan metabolism in the 3-nitropropionic acid model of Huntington's disease. Pharmacology, Biochemistry, and Behavior. 132: 115-124. PMID 25773340 DOI: 10.1016/J.Pbb.2015.03.002 |
0.411 |
|
| 2015 |
Török R, Kónya JA, Zádori D, Veres G, Szalárdy L, Vécsei L, Klivényi P. mRNA expression levels of PGC-1α in a transgenic and a toxin model of Huntington's disease. Cellular and Molecular Neurobiology. 35: 293-301. PMID 25319408 DOI: 10.1007/S10571-014-0124-Z |
0.322 |
|
| 2014 |
Zádori D, Veres G, Szalárdy L, Klivényi P, Toldi J, Vécsei L. Glutamatergic dysfunctioning in Alzheimer's disease and related therapeutic targets. Journal of Alzheimer's Disease : Jad. 42: S177-87. PMID 24670398 DOI: 10.3233/Jad-132621 |
0.32 |
|
| 2013 |
Török R, Török N, Szalardy L, Plangar I, Szolnoki Z, Somogyvari F, Vecsei L, Klivenyi P. Association of vitamin D receptor gene polymorphisms and Parkinson's disease in Hungarians. Neuroscience Letters. 551: 70-4. PMID 23880018 DOI: 10.1016/J.Neulet.2013.07.014 |
0.304 |
|
| 2013 |
Szalardy L, Zadori D, Plangar I, Vecsei L, Weydt P, Ludolph AC, Klivenyi P, Kovacs GG. Neuropathology of partial PGC-1α deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative diseases. Neuro-Degenerative Diseases. 12: 177-88. PMID 23406886 DOI: 10.1159/000346267 |
0.395 |
|
| 2013 |
Molnar M, Szalardy L, Zadori D, Vecsei L, Klivenyi P. Revisiting the observation of anxiety-like behavior and assessing phenotypic progression in PGC-1α-deficient mice Journal of the Neurological Sciences. 333: e727. DOI: 10.1016/J.Jns.2013.07.2508 |
0.316 |
|
| 2012 |
Szalardy L, Zadori D, Toldi J, Fulop F, Klivenyi P, Vecsei L. Manipulating kynurenic acid levels in the brain - on the edge between neuroprotection and cognitive dysfunction. Current Topics in Medicinal Chemistry. 12: 1797-806. PMID 23030614 DOI: 10.2174/156802612803989264 |
0.308 |
|
| 2012 |
Nemeth D, Dye CD, Sefcsik T, Janacsek K, Turi Z, Londe Z, Klivenyi P, Kincses ZT, Szabó N, Vecsei L, Ullman MT. Language deficits in pre-symptomatic Huntington's disease: evidence from Hungarian. Brain and Language. 121: 248-53. PMID 22538085 DOI: 10.1016/J.Bandl.2012.04.001 |
0.315 |
|
| 2012 |
Szalardy L, Klivenyi P, Zadori D, Fulop F, Toldi J, Vecsei L. Mitochondrial disturbances, tryptophan metabolites and neurodegeneration: medicinal chemistry aspects. Current Medicinal Chemistry. 19: 1899-920. PMID 22429096 DOI: 10.2174/092986712800167365 |
0.372 |
|
| 2011 |
Klivenyi P, Vecsei L. Pharmacological models of Parkinson's disease in rodents. Methods in Molecular Biology (Clifton, N.J.). 793: 211-27. PMID 21913103 DOI: 10.1007/978-1-61779-328-8_14 |
0.41 |
|
| 2010 |
Spitzer P, Klafki HW, Blennow K, Buée L, Esselmann H, Herruka SK, Jimenez C, Klivenyi P, Lewczuk P, Maler JM, Markus K, Meyer HE, Morris C, Müller T, Otto M, et al. cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease. 2010. PMID 20886057 DOI: 10.4061/2010/548145 |
0.308 |
|
| 2010 |
Vamos E, Voros K, Vecsei L, Klivenyi P. Neuroprotective effects of L-carnitine in a transgenic animal model of Huntington's disease. Biomedicine & Pharmacotherapy = Biomã©Decine & Pharmacothã©Rapie. 64: 282-6. PMID 19932584 DOI: 10.1016/J.Biopha.2009.06.020 |
0.411 |
|
| 2010 |
Klivenyi P, Vecsei L. Novel therapeutic strategies in Parkinson's disease. European Journal of Clinical Pharmacology. 66: 119-25. PMID 19834698 DOI: 10.1007/S00228-009-0742-4 |
0.362 |
|
| 2009 |
Vamos E, Voros K, Zadori D, Vecsei L, Klivenyi P. Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 116: 1079-86. PMID 19551467 DOI: 10.1007/S00702-009-0253-6 |
0.451 |
|
| 2009 |
Vamos E, Csati A, Vecsei L, Klivenyi P. Effects of valproate on the dopaminergic system in mice. Neurological Research. 31: 217-9. PMID 18768113 DOI: 10.1179/174313208X346099 |
0.4 |
|
| 2007 |
Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Peripheral kynurenine metabolism in focal dystonia. Medicinal Chemistry (ShäRiqah (United Arab Emirates)). 3: 285-8. PMID 17504201 DOI: 10.2174/157340607780620707 |
0.336 |
|
| 2007 |
Vamos E, Csati A, Klivenyi P, Vecsei L. 1.319 Effects of valproate on dopaminergic system in mice Parkinsonism & Related Disorders. 13. DOI: 10.1016/S1353-8020(08)70554-6 |
0.408 |
|
| 2006 |
Klivenyi P, Bende Z, Hartai Z, Penke Z, Nemeth H, Toldi J, Vecsei L. Behaviour changes in a transgenic model of Huntington's disease. Behavioural Brain Research. 169: 137-41. PMID 16443291 DOI: 10.1016/J.Bbr.2006.01.003 |
0.423 |
|
| 2006 |
Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease. 21: 541-8. PMID 16298531 DOI: 10.1016/J.Nbd.2005.08.018 |
0.787 |
|
| 2005 |
Klivenyi P, Kekesi KA, Hartai Z, Juhasz G, Vecsei L. Effects of mitochondrial toxins on the brain amino acid concentrations. Neurochemical Research. 30: 1421-7. PMID 16341939 DOI: 10.1007/S11064-005-8512-X |
0.367 |
|
| 2005 |
Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. Journal of the Neurological Sciences. 239: 31-5. PMID 16099471 DOI: 10.1016/J.Jns.2005.07.006 |
0.339 |
|
| 2005 |
Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L. Kynurenine metabolism in multiple sclerosis. Acta Neurologica Scandinavica. 112: 93-6. PMID 16008534 DOI: 10.1111/J.1600-0404.2005.00442.X |
0.305 |
|
| 2005 |
Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63. PMID 15494404 DOI: 10.1074/Jbc.M410210200 |
0.792 |
|
| 2004 |
Klivenyi P, Gardian G, Calingasan NY, Yang L, von Borstel R, Saydoff J, Browne SE, Beal MF. Neuroprotective effects of oral administration of triacetyluridine against MPTP neurotoxicity. Neuromolecular Medicine. 6: 87-92. PMID 15970626 DOI: 10.1385/Nmm:6:2-3:087 |
0.796 |
|
| 2004 |
Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Medicine. 5: 235-41. PMID 15626823 DOI: 10.1385/Nmm:5:3:235 |
0.799 |
|
| 2004 |
Klivenyi P, Calingasan NY, Starkov A, Stavrovskaya IG, Kristal BS, Yang L, Wieringa B, Beal MF. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiology of Disease. 15: 610-7. PMID 15056469 DOI: 10.1016/J.Nbd.2003.12.014 |
0.722 |
|
| 2004 |
Klivenyi P, Starkov AA, Calingasan NY, Gardian G, Browne SE, Yang L, Bubber P, Gibson GE, Patel MS, Beal MF. Mice deficient in dihydrolipoamide dehydrogenase show increased vulnerability to MPTP, malonate and 3-nitropropionic acid neurotoxicity. Journal of Neurochemistry. 88: 1352-60. PMID 15009635 DOI: 10.1046/J.1471-4159.2003.02263.X |
0.804 |
|
| 2004 |
Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry. 88: 576-82. PMID 14720207 DOI: 10.1046/J.1471-4159.2003.02160.X |
0.789 |
|
| 2003 |
Klivenyi P, Gardian G, Calingasan NY, Yang L, Beal MF. Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Journal of Molecular Neuroscience : Mn. 21: 191-8. PMID 14645986 DOI: 10.1385/Jmn:21:3:191 |
0.798 |
|
| 2003 |
Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K, Perrier AL, Bruses J, Rubio ME, Topf N, Tabar V, Harrison NL, Beal MF, Moore MA, Studer L. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nature Biotechnology. 21: 1200-7. PMID 14502203 DOI: 10.1038/Nbt870 |
0.505 |
|
| 2003 |
Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 86: 267-72. PMID 12807446 DOI: 10.1046/J.1471-4159.2003.T01-1-01868.X |
0.8 |
|
| 2003 |
Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Erratum: Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease (Journal of Neurochemistry (2003) 86 (267-272)) Journal of Neurochemistry. 87. DOI: 10.1046/J.1471-4159.2003.01868.X |
0.79 |
|
| 2001 |
Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Dedeoglu A, Albers DS, Kowall NW, Beal MF. Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid. Experimental Neurology. 168: 356-63. PMID 11259123 DOI: 10.1006/Exnr.2001.7627 |
0.65 |
|
| 2001 |
Klivenyi P, Karg E, Rozsa C, Horvath R, Komoly S, Nemeth I, Turi S, Vecsei L. alpha-Tocopherol/lipid ratio in blood is decreased in patients with Leber's hereditary optic neuropathy and asymptomatic carriers of the 11778 mtDNA mutation. Journal of Neurology, Neurosurgery, and Psychiatry. 70: 359-62. PMID 11181859 DOI: 10.1136/Jnnp.70.3.359 |
0.316 |
|
| 2001 |
Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, Carlson EJ, Epstein CJ, Beal MF. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Experimental Neurology. 167: 189-95. PMID 11161607 DOI: 10.1006/Exnr.2000.7525 |
0.665 |
|
| 2000 |
Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 11: 2491-3. PMID 10943709 DOI: 10.1097/00001756-200008030-00029 |
0.611 |
|
| 2000 |
Andreassen OA, Ferrante RJ, Hughes DB, Klivenyi P, Dedeoglu A, Ona VO, Friedlander RM, Beal MF. Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. Journal of Neurochemistry. 75: 847-52. PMID 10899963 DOI: 10.1046/J.1471-4159.2000.0750847.X |
0.623 |
|
| 2000 |
Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D, Beal MF. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport. 11: 1265-8. PMID 10817604 DOI: 10.1097/00001756-200004270-00024 |
0.763 |
|
| 2000 |
Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. Journal of Neurochemistry. 74: 2108-19. PMID 10800956 DOI: 10.1046/J.1471-4159.2000.0742108.X |
0.618 |
|
| 2000 |
Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Shinobu LA, Epstein CJ, Beal MF. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology. 47: 447-55. PMID 10762155 DOI: 10.1002/1531-8249(200004)47:4<447::Aid-Ana7>3.0.Co;2-R |
0.78 |
|
| 2000 |
Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 1-7. PMID 10627575 DOI: 10.1523/Jneurosci.20-01-00001.2000 |
0.782 |
|
| 1999 |
Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Experimental Neurology. 157: 142-9. PMID 10222117 DOI: 10.1006/Exnr.1999.7049 |
0.77 |
|
| 1999 |
Matthews RT, Klivenyi P, Mueller G, Yang L, Wermer M, Thomas CE, Beal MF. Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Experimental Neurology. 157: 120-6. PMID 10222114 DOI: 10.1006/Exnr.1999.7045 |
0.731 |
|
| 1999 |
Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 5: 347-50. PMID 10086395 DOI: 10.1038/6568 |
0.707 |
|
| 1998 |
Klivenyi P, St Clair D, Wermer M, Yen HC, Oberley T, Yang L, Flint Beal M. Manganese superoxide dismutase overexpression attenuates MPTP toxicity. Neurobiology of Disease. 5: 253-8. PMID 9848095 DOI: 10.1006/Nbdi.1998.0191 |
0.68 |
|
| 1998 |
Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. Journal of Neurochemistry. 71: 2642-4. PMID 9832167 DOI: 10.1046/J.1471-4159.1998.71062642.X |
0.583 |
|
| 1998 |
Klivenyi P, Beal MF, Ferrante RJ, Andreassen OA, Wermer M, Chin MR, Bonventre JV. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. Journal of Neurochemistry. 71: 2634-7. PMID 9832165 DOI: 10.1046/J.1471-4159.1998.71062634.X |
0.618 |
|
| 1998 |
Klivenyi P, Matthews RT, Wermer M, Yang L, MacGarvey U, Becker DA, Natero R, Beal MF. Azulenyl nitrone spin traps protect against MPTP neurotoxicity. Experimental Neurology. 152: 163-6. PMID 9682023 DOI: 10.1006/Exnr.1998.6824 |
0.675 |
|
| 1995 |
Vécsei L, Klivényi P. Somatostatin and Alzheimer's disease. Archives of Gerontology and Geriatrics. 21: 35-41. PMID 15374222 DOI: 10.1016/0167-4943(95)00640-7 |
0.369 |
|
| Show low-probability matches. |